Daniel R. Chevallard, Chief Financial Officer at LENZ Therapeutics, Inc. (LENZ), bought 7,500 shares at $8.57 ($64K) on 2026-03-27, disclosed to the SEC on 2026-03-30.
CFO Daniel R. Chevallard purchased 7,500 shares at $8.57 on March 27, 2026, marking the largest insider purchase in the company's history. This significant buy by C-suite leadership during a steep 90-day decline of 48.57% suggests confidence in the stock's recovery potential.
The stock has crashed 48.57% over the last 90 days and is down 67.67% over the past year, trading just 0.48% above its 52-week low of $8.25.
The stock faces headwinds from an analyst downgrade on May 16, 2026, and a significant cut to consensus EPS estimates on May 14, 2026.
Several strong factors at once. The rarest rating we give.
| Filing → |
| VIRX | SELL | 2024-02-27 | $2K | — | Filing → |
| VIRX | SELL | 2023-11-28 | $2K | — | Filing → |
| VIRX | SELL | 2023-08-29 | $5K | — | Filing → |